IMPORTANT HEARTWARE INTERNATIONAL SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Commenced Against HeartWare International, Inc. in the Southern District of New York -- HTWR

NEW YORK, Jan. 29, 2016 -- Wolf Haldenstein Adler Freeman & Herz LLP  announces  that  a class action  lawsuit  has been  filed on behalf of investors who purchased HeartWare International, Inc. (“HeartWare” or the "Company") (NASDAQ:HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”) in the United States District Court for the Southern District of New York.

Shareholders who incurred losses on shares of HeartWare International, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.

If you purchased the shares of  HeartWare International, Inc. during the period June 10, 2014 and January 11, 2016, inclusive, you may, no later than March 22, 2016, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that after the U.S. Food and Drug Administration ("FDA") issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company's sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that they therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing.

The truth concerning the Company's failure to remediate the regulatory failures identified by the FDA and its impact on the viability of MVAD was revealed through a series of disclosures. On September 1, 2015, HeartWare announced a highly dilutive acquisition of Valtech Cardio, Ltd., a manufacturer of medical devices used to treat heart disease. The Complaint alleges that this disclosure revealed significant obstacles to the timely approval of MVAD. On September 9, 2015, HeartWare disclosed that it was halting enrollment in the MVAD trial because of a manufacturing problem with the device.

On October 12, 2015, HeartWare disclosed that patients in the MVAD trial had suffered adverse events, and that the trial would be further delayed. On January 11, 2016, the Company revealed that problems with MVAD had resulted in serious adverse events in nearly half of the patients so far implanted with the device, and that the trial would be delayed indefinitely.

In response to each of these disclosures, the price of HeartWare's common stock declined significantly. HeartWare's common stock has fallen 72% from its Class Period high of $94.47 on April 10, 2015,  to close at $26.50 per share on January 12, 2016.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.  All e-mail correspondence should make reference to the “HeartWare Investigation.”

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Contact:

Wolf Haldenstein Adler Freeman &  Herz LLP 
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774